Mitoxantrone as first line cytotoxic therapy in advanced breast cancer: preliminary results of a phase II study.
Mitoxantrone, 14 mg/m2 repeated every 3 weeks was administered to postmenopausal patients with advanced measurable breast cancer previously untreated with cytotoxic agents. Response was achieved in 16 out of 28 (44%) evaluable patients and in four of the patients (with soft tissue disease) the response was complete. The median duration of response was 10+ months with a range from 4-12+ months. At doses which cause significant hematological toxicity other objective and subjective toxicities were remarkably mild.
D000368:Aged; D000880:Anthraquinones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001769:Blood / Q000187:drug effects; D001943:Breast Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007364:Intercalating Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D008942:Mitoxantrone; D013997:Time Factors
D000880:Anthraquinones; D000970:Antineoplastic Agents; D007364:Intercalating Agents; D008942:Mitoxantrone